FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2039278712> ?p ?o ?g. }

• W2039278712 endingPage "237" @default.
• W2039278712 startingPage "230" @default.
• W2039278712 abstract "In addition to P-glycoprotein (Pgp), 2 proteins related to multidrug resistance (MDR) have recently been described. The Multidrug-Resistance-associated protein (MRP) is one of the ATP-binding-cassette (ABC) transporters. The Lung-Resistance Protein (LRP) is the major component of human vaults, which are newly described cellular organelles and thought to mediate intracellular transport processes. Using immunocytochemical methods, we have examined the expression of MRP and LRP among panels of human cancer-cell lines not selected for drug resistance which have been previously characterized for expression of Pgp, and in vitro response to a variety of anti-cancer drugs. Expression of MRP and LRP was observed in 47/55 (87%) and 46/59 (78%) cell lines, respectively. Statistically significant correlations were observed between expression of each of these 3 proteins and in vitro sensitivity to at least one drug classically associated with MDR. LRP showed the greatest individual predictive value, which also applied to several non-classical MDR drugs. Co-expression of 2–3 MDR-related proteins was observed in 64% of the lines and was, in general, associated with high relative levels of drug resistance. Previously identified “classic” MDR lines as well as “pan-resistant” lines concurrently expressed all 3 MDR-related proteins. Some highly drug-resistant cell lines without detectable MDRI/Pgp were found to express relatively high levels of MRP and LRP. The high prevalence of MRP and LRP expression observed in this large set of cell lines, which have not been subjected to laboratory drug selection, suggests that MDR mechanisms associated with these proteins may be widespread in human malignancies. Moreover, the overlapping of these more recently recognized MDR phenotypes with Pgp-type MDR results in a complex phenotype, the understanding of which may be of importance in the development of new drugs and design of clinical treatment protocols, particularly those seeking to employ strategies to reverse the MDR phenotype. © 1996 Wiley-Liss, Inc." @default.
• W2039278712 created "2016-06-24" @default.
• W2039278712 creator A5049292621 @default.
• W2039278712 creator A5051644644 @default.
• W2039278712 creator A5061124310 @default.
• W2039278712 creator A5075656335 @default.
• W2039278712 creator A5079948759 @default.
• W2039278712 creator A5084816440 @default.
• W2039278712 creator A5085426388 @default.
• W2039278712 date "1996-01-17" @default.
• W2039278712 modified "2023-10-18" @default.
• W2039278712 title "Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines" @default.
• W2039278712 cites W1886830245 @default.
• W2039278712 cites W1978459262 @default.
• W2039278712 cites W1986012975 @default.
• W2039278712 cites W2017731672 @default.
• W2039278712 cites W2026825995 @default.
• W2039278712 cites W2030663566 @default.
• W2039278712 cites W2032168527 @default.
• W2039278712 cites W2041995665 @default.
• W2039278712 cites W2067898376 @default.
• W2039278712 cites W2077140502 @default.
• W2039278712 cites W2142385577 @default.
• W2039278712 cites W2149392683 @default.
• W2039278712 cites W2155208683 @default.
• W2039278712 cites W2168070336 @default.
• W2039278712 cites W2168095256 @default.
• W2039278712 cites W2171344824 @default.
• W2039278712 doi "https://doi.org/10.1002/(sici)1097-0215(19960117)65:2<230::aid-ijc17>3.0.co;2-h" @default.
• W2039278712 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8567122" @default.
• W2039278712 hasPublicationYear "1996" @default.
• W2039278712 type Work @default.
• W2039278712 sameAs 2039278712 @default.
• W2039278712 citedByCount "202" @default.
• W2039278712 countsByYear W20392787122012 @default.
• W2039278712 countsByYear W20392787122013 @default.
• W2039278712 countsByYear W20392787122014 @default.
• W2039278712 countsByYear W20392787122015 @default.
• W2039278712 countsByYear W20392787122016 @default.
• W2039278712 countsByYear W20392787122017 @default.
• W2039278712 countsByYear W20392787122018 @default.
• W2039278712 countsByYear W20392787122019 @default.
• W2039278712 countsByYear W20392787122020 @default.
• W2039278712 countsByYear W20392787122021 @default.
• W2039278712 countsByYear W20392787122022 @default.
• W2039278712 countsByYear W20392787122023 @default.
• W2039278712 crossrefType "journal-article" @default.
• W2039278712 hasAuthorship W2039278712A5049292621 @default.
• W2039278712 hasAuthorship W2039278712A5051644644 @default.
• W2039278712 hasAuthorship W2039278712A5061124310 @default.
• W2039278712 hasAuthorship W2039278712A5075656335 @default.
• W2039278712 hasAuthorship W2039278712A5079948759 @default.
• W2039278712 hasAuthorship W2039278712A5084816440 @default.
• W2039278712 hasAuthorship W2039278712A5085426388 @default.
• W2039278712 hasConcept C104317684 @default.
• W2039278712 hasConcept C114851261 @default.
• W2039278712 hasConcept C121608353 @default.
• W2039278712 hasConcept C133936738 @default.
• W2039278712 hasConcept C149011108 @default.
• W2039278712 hasConcept C200082930 @default.
• W2039278712 hasConcept C202751555 @default.
• W2039278712 hasConcept C2778707650 @default.
• W2039278712 hasConcept C2910769707 @default.
• W2039278712 hasConcept C44312359 @default.
• W2039278712 hasConcept C502942594 @default.
• W2039278712 hasConcept C512196 @default.
• W2039278712 hasConcept C54355233 @default.
• W2039278712 hasConcept C81885089 @default.
• W2039278712 hasConcept C86803240 @default.
• W2039278712 hasConcept C96232424 @default.
• W2039278712 hasConceptScore W2039278712C104317684 @default.
• W2039278712 hasConceptScore W2039278712C114851261 @default.
• W2039278712 hasConceptScore W2039278712C121608353 @default.
• W2039278712 hasConceptScore W2039278712C133936738 @default.
• W2039278712 hasConceptScore W2039278712C149011108 @default.
• W2039278712 hasConceptScore W2039278712C200082930 @default.
• W2039278712 hasConceptScore W2039278712C202751555 @default.
• W2039278712 hasConceptScore W2039278712C2778707650 @default.
• W2039278712 hasConceptScore W2039278712C2910769707 @default.
• W2039278712 hasConceptScore W2039278712C44312359 @default.
• W2039278712 hasConceptScore W2039278712C502942594 @default.
• W2039278712 hasConceptScore W2039278712C512196 @default.
• W2039278712 hasConceptScore W2039278712C54355233 @default.
• W2039278712 hasConceptScore W2039278712C81885089 @default.
• W2039278712 hasConceptScore W2039278712C86803240 @default.
• W2039278712 hasConceptScore W2039278712C96232424 @default.
• W2039278712 hasIssue "2" @default.
• W2039278712 hasLocation W20392787121 @default.
• W2039278712 hasLocation W20392787122 @default.
• W2039278712 hasOpenAccess W2039278712 @default.
• W2039278712 hasPrimaryLocation W20392787121 @default.
• W2039278712 hasRelatedWork W1965455284 @default.
• W2039278712 hasRelatedWork W1997813700 @default.
• W2039278712 hasRelatedWork W2029717892 @default.
• W2039278712 hasRelatedWork W2048083250 @default.
• W2039278712 hasRelatedWork W2077014633 @default.
• W2039278712 hasRelatedWork W2126585177 @default.
• W2039278712 hasRelatedWork W2148365177 @default.

• next